Drug Profile

Timtraxanib - Avixgen

Alternative Names: AVI-3207

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Avixgen
Developer Avixgen; Bixzen; Ebixen
Class Eye disorder therapies; Peptides
Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

No development reported Age-related macular degeneration; Diabetic macular oedema

28 May 2025 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in South Korea (Intravitreous, Injection)
25 May 2023 Timtraxanib is still in phase I trials for Age-related-acular-degeneration in South Korea (Avixgen pipeline, May 2023)
28 Oct 2022 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in South Korea

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com